Spectral-domain optical coherence tomography assessment of retinal and choroidal changes in patients with coronavirus disease 2019: a case-control study

Mojtaba Abrishami1, Ramin Daneshvar1, Zahra Emamverdian1, Neda Saeedian2, Fariba Tohidinezhad3, Saeid Eslami3,4 and Mohammad-Reza Ansari-Astaneh1*

Abstract
Objectives: This study aimed to evaluate the retinal and choroidal changes in the macular region of patients with Coronavirus Disease 2019 (COVID-19) using structural spectral-domain optical coherence tomography (SD-OCT) analysis.

Methods: This cross-sectional observational case-control study included patients recovered from COVID-19. The COVID-19 in all participants was confirmed using the reverse transcription-polymerase chain reaction (RT-PCR) technique. The participants had mild to moderate degree of disease without a history of hospitalization, steroid usage, or blood saturation below 92%. Macular SD-OCT was performed at least two weeks and up to one month after recovery from systemic COVID-19. Quantitative and qualitative changes detected by macular SD-OCT imaging were evaluated in COVID-19 recovered patients and compared with the results of age-matched normal controls.

Results: Participants in this study included 30 cases (60 eyes) and 60 healthy controls (120 eyes). In total, 17 (28.3%) eyes in patient group showed at least one abnormal finding indicated by macular SD-OCT imaging included hyper-reflective lesions in different retinal layers. In addition, dilated choroidal vessels and retinal pigment epitheliopathy were evident in 41 (68.3.6%) and 4 (6.6%) eyes in patient group, respectively, and their OCT findings resembled those with pachychoroid spectrum. No statistically significant differences were observed in retinal layers or retinal volume between the two groups. The mean ± SD subfoveal choroidal thickness (SFCT) was determined at 380.3 ± 12.40 μm, which was significantly thicker than that in control group (310.7 ± 57.5 μm) (P < 0.001).

Conclusion: Regarding retinal thickness, no significant change was observed in different retina layers of patients with COVID-19; however, there were striking qualitative changes, such as hyperreflective lesions in different retinal layers. The evaluation of choroidal structure and thickness demonstrated remarkable abnormal pachyvessels and significant thickening of the SFCT but the clinical significance of these findings is unknown.

Keywords: Choroid, Coronavirus disease 2019, Macula, Retina, Severe acute respiratory syndrome Coronavirus 2, Spectral-domain optical coherence tomography

Introduction
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a highly contagious infection with multi-organ involvement. Neurological manifestations have been reported throughout the disease course.
Therefore, the potential involvement of the Central Nervous System (CNS) has been proposed in Coronavirus Disease 2019 (COVID-19) [1]. Since SARS-CoV-2 enters human cells by binding to the Angiotensin-Converting Enzyme (ACE2) 2 receptor; cells containing ACE2 are vulnerable to SARS-CoV-2 infection [2]. In addition to the lung alveolar cells, neurons, and glial cells in the CNS, several retinal components, including Müller cells, ganglion cells, retinal vascular endothelial cells (BRECs), and photoreceptor cells also contain ACE2 receptors [3]. Therefore, ocular tissue involvement is expected in the course of the disease. The most common and easily identifiable ocular manifestations of the SARS-CoV-2 have been reported in the ocular surface (e.g. conjunctival hyperemia, chemosis, and epiphora) [4–10].

Spectral-Domain Optical Coherence Tomography (SD-OCT) is a non-invasive imaging modality with high resolution that can be used for the cross-sectional evaluation of the retina. Several studies have been conducted on changes in choroidal and retinal structure, as well as thickness and vascularity worldwide; however, the results are very inconsistent [11–27]. This study aimed to evaluate the retinal and choroidal changes in the macular region of patients with COVID-19, both qualitatively and quantitatively, using structural SD-OCT analysis and compare the results with those obtained from a control group.

Methods

Study participants

This cross-sectional study was conducted in Imam Reza General Clinic, one of the largest centers devoted to COVID-19 patients in Mashhad, Iran. Patients recovered from COVID-19 were included in the study. All included subjects had a definite diagnosis of COVID-19 that had been confirmed through a positive real-time, reverse transcription-polymerase chain reaction (RT-PCR) assay as well as the test result of nasopharyngeal swab sample. The recovery period of these patients lasted from two weeks to not more than one month. Patients with a past medical history of diabetes mellitus, systemic hypertension, renal failure, proteinuria, or dementia, those with a history of any intraocular surgery and any significant refractive errors including pathologic myopia or high hyperopia, were excluded from the study. In addition, the patients with a history of more than mild diseases, including oxygen saturation less than 94% in room air at the course of the disease and those with any need for hospitalization or steroid usage were excluded to eliminate the confounding factors that might affect the study results. A control group was retrospectively selected from participants in an ongoing PERSIAN cohort study in Mashhad University of Medical Sciences, Mashhad, Iran [28]. The individuals in the control group were examined before January 2020, one month before the first report of a confirmed case of COVID-19 in the region.

OCT image acquisition

The macular area of eligible subjects was imaged using SD-OCT (AngioVue, Optovue RTVue XR Avanti, Optovue, Fremont, CA). The device uses a laser beam with a wavelength of 840 nm and a scan rate of 70 kHz to obtain the images. Raster, Cross Line, Enhanced HD Line, and Retina Map protocols were used to evaluate the retina and choroid in the macular region of the patients. A panel of three experienced examiners (MA, MRAA, RD) evaluated each OCT image to pinpoint any retinal or choroidal finding and measure the subfoveal choroidal thickness (SFCT) and SD-OCT image segmentation accuracy. Any disagreement was resolved by discussion and consensus of all examiners. The SFCT was measured using the Crossline Images. Briefly, each horizontal or vertical foveal scan of the device is an average of at least twenty B-scan of the macular area with a width of 10 mm, and these horizontal and vertical ‘crosslines’ are centered at the fovea and perpendicular to each other. The ‘Caliper tool’ within Optovue machine software (version 2018.0.0.14) was used to measure the SFCT and determine the minimum distance between the outer aspect of Bruch’s membrane (identified as a hyperreflective line) and the sclera border (i.e., the innermost hyperreflective line of the choriocapillary interface). The measurement was repeated in both horizontal and vertical scans and the average was considered to determine SFCT. Pachychoroid pigmentation is defined as dilatation of the large choroidal vessels compressing the overlying choriocapillaris and Sattler’s layer. Pachychoroid pigment epitheliopathy is defined by OCT as numerous, scattered small elevations of the RPE representing RPE hyperplasia and sub-RPE drusen-like deposits and/or small serous PEDs [29]. Raster and Retina Map protocols of the device software were used to evaluate the following retinal thicknesses in the macular area: full retina (internal limiting membrane [ILM]) to Bruch membrane [BRM]), inner retina (ILM to the interface of the inner plexiform layer [IPL] and the inner nuclear layer [INL]), and outer retina (interface of the IPL and INL to BRM). The macular area was separated into three concentric circles: the fovea (central circle, with a diameter of 1 mm), the parafovea (inner diameter of 1 mm and outer diameter of 3 mm) and the perifovea (inner diameter of 3 mm and outer diameter of 5 mm). All subjects in both groups were examined using the same machine. All images with a signal strength index (SSI) of less than 50 were excluded. For each subject, the SD-OCT image of the eye
with better SSI was included. The readers were blind on the status of the patients.

**Statistical analysis**

Statistical analysis was performed using the SPSS software (Version 20; IBM SPSS Statistics, IBM Corporation, Chicago, IL, USA). Quantitative and categorical variables were presented with descriptive statistics (by providing central tendency measures for continuous variables) and frequencies. The normal distribution of variables was evaluated using the Shapiro-Wilk test and normality plots. Based on the data distribution, the independent samples t-test or Mann-Whitney U test was used to compare thickness measurements between the independent samples (control and case groups). A \( p \)-value less than or equal to 0.05 was considered statistically significant for all tests.

**Ethical considerations**

The study protocol adhered to the tenets of the 1964 Declaration of Helsinki and its later amendment. The written informed consent was obtained from all participants in the study, and participation in this study was voluntary and based on willingness. The study protocol was approved by the Medical Ethics Committee at the Mashhad University of Medical Sciences, Mashhad, Iran (IR. MUMS.REC.1399.104).

**Results**

This study was conducted on 60 eyes of 30 patients (52.9% male) with the mean ± SD age of 39.6 ± 1.7 years, and 120 eyes of 60 healthy controls (31 males) with a mean ± SD age of 39.3 ± 7.7 years. There was no significant difference between the two groups in terms of age \( (P = 0.263) \) and gender \( (P = 0.635) \). The mean ± SD SSI was 75.7 ± 6.8 in the COVID-19 cases and 72.3 ± 8.3 in the normal controls \( (P = 0.181) \).

**Macular retinal analysis**

At least one abnormal finding, such as hyperreflective lesions, was observed in the images of 17 eyes (28.3%) in different retinal layers in patient group. Qualitatively, these SD-OCT features included hyperreflective lesions in retinal ganglion cell layer (GCL) \( (n = 11, 18.3\%) \), retinal nerve fiber layer (RNFL) \( (n = 7, 11.7\%) \), outer plexiform layer (OPL) \( (n = 5, 8.3\%) \), inner plexiform layer (IPL) \( (n = 4, 6.7\%) \), inner nuclear layer (INL) \( (n = 4, 6.7\%) \), outer nuclear layer (ONL) \( (n = 2, 3.3\%) \), external limiting membrane (ELM) \( (n = 1, 1.7\%) \) (Figs. 1, 2, and 3).

As shown in Table 1, the difference in the full retinal thickness of the case and control groups in parafoveal \( (311.2 ± 19.0 \text{ vs. } 308.9 ± 14.1, \text{ respectively}; P = 0.606) \) and perifoveal \( (285.4 ± 16.3 \text{ vs. } 282.7 ± 10.1, \text{ respectively}; P = 0.142) \) rings were not statistically significant. A not statistically significant increase was also observed in the inner (parafovea: \( 129.1 ± 9.6 \text{ vs. } 128.1 ± 7.4, P = 0.629 \); perifovea: \( 113.9 ± 8.1 \text{ vs. } 112.7 ± 5.3, P = 0.563 \))

![Fig. 1](Image) Spectral domain optical coherence tomography finding of macular area in a representative patient with coronavirus disease 2019. Note the hyperreflective bands in different retinal layers (white arrows) and dilated choroidal vessels (asterisks)
Fig. 2 Spectral domain optical coherence tomography finding of macular area in a representative patient with coronavirus disease 2019. Note marked thickening of the choroid, the hyperreflective bands in outer nuclear layer/outer plexiform layer (red arrow) and the external limiting membrane (vertical white arrow).

Fig. 3 Spectral domain optical coherence tomography finding of macular area in a representative patient with coronavirus disease 2019. Note the dilated choroidal vessels (asterisks), and overlying retinal pigment epitheliopathy (white arrows). The findings are similar to those in pachychoroid spectrum.
Table 1  Comparison of the Full Retinal Thickness between the COVID-19 Patients (*N* = 25) and Control Group (*N* = 60)

| Variable     | Retinal Thickness | Retinal Volume |
|--------------|-------------------|----------------|
|              | Control           | Case           | *P*-value | Control           | Case           | *P*-value |
| Fovea        | 245.7 ± 20.0      | 248.3 ± 20.5   | 0.407     | 0.193 ± 0.016     | 0.195 ± 0.016 | 0.415     |
| Parafovea    | 308.9 ± 14.1      | 311.2 ± 19.0   | 0.606     | 1.940 ± 0.088     | 1.954 ± 0.119 | 0.633     |
| S Hemisphere | 308.7 ± 13.7      | 312.2 ± 18.6   | 0.417     | 0.970 ± 0.043     | 0.981 ± 0.058 | 0.423     |
| I Hemisphere | 308.9 ± 14.9      | 310.1 ± 19.5   | 0.794     | 0.971 ± 0.047     | 0.974 ± 0.061 | 0.813     |
| Temporal     | 299.5 ± 14.6      | 303.8 ± 19.2   | 0.265     | 0.470 ± 0.023     | 0.485 ± 0.045 | 0.137     |
| Superior     | 312.6 ± 13.0      | 315.3 ± 18.4   | 0.46      | 0.491 ± 0.020     | 0.495 ± 0.029 | 0.429     |
| Nasal        | 311.7 ± 16.5      | 314.1 ± 19.2   | 0.654     | 0.490 ± 0.026     | 0.493 ± 0.030 | 0.63      |
| Inferior     | 311.6 ± 14.7      | 311.2 ± 20.5   | 0.965     | 0.489 ± 0.023     | 0.489 ± 0.032 | 0.923     |
| Perifovea    | 282.7 ± 10.1      | 285.4 ± 16.3   | 0.142     | 3.552 ± 0.127     | 3.587 ± 0.204 | 0.147     |
| S Hemisphere | 284.6 ± 10.1      | 287.9 ± 16.2   | 0.124     | 1.788 ± 0.064     | 1.809 ± 0.101 | 0.117     |
| I Hemisphere | 280.8 ± 10.8      | 283.0 ± 16.9   | 0.257     | 1.764 ± 0.068     | 1.778 ± 0.106 | 0.267     |
| Temporal     | 271.9 ± 11.1      | 276.0 ± 15.4   | 0.077     | 0.853 ± 0.035     | 0.867 ± 0.048 | 0.056     |
| Superior     | 284.3 ± 10.4      | 287.8 ± 17.1   | 0.089     | 0.893 ± 0.033     | 0.904 ± 0.053 | 0.093     |
| Nasal        | 298.1 ± 11.7      | 299.9 ± 17.7   | 0.518     | 0.936 ± 0.037     | 0.942 ± 0.055 | 0.475     |
| Inferior     | 276.4 ± 11.2      | 278.1 ± 17.3   | 0.377     | 0.868 ± 0.035     | 0.874 ± 0.054 | 0.357     |

Notes: The unit of measurement thicknesses and volumes were μm and mm³, respectively. Values represented as mean ± SD and analysis made by Mann-Whitney U test.

Abbreviations: S superior, I inferior

*P* = 0.200 and outer (parafovea: 181.9 ± 10.5 vs. 180.7 ± 8.7, *p* = 0.559; perifovea: 171.6 ± 8.9 vs. 170.1 ± 6.7, *p* = 0.175) retinal thicknesses that were not statistically significant (Tables 2, 3). It is worth mentioning that no statistically significant difference in foveal thickness was observed between the case and control groups in inner, outer, or full retinal thickness analysis. Moreover, retinal volumes were also increased in different layers of the retina that was not statistically significant (Tables 1, 2, and 3).

Table 2  Comparison of the Inner Retinal Thickness between the COVID-19 Patients (*N* = 25) and Control Group (*N* = 60)

| Variable     | Retinal Thickness | Retinal Volume |
|--------------|-------------------|----------------|
|              | Control           | Case           | *P*-value | Control           | Case           | *P*-value |
| Fovea        | 67.8 ± 11.4       | 68.6 ± 12.3    | 0.675     | 0.053 ± 0.009     | 0.054 ± 0.010 | 0.616     |
| Parafovea    | 128.1 ± 7.4       | 129.1 ± 9.6    | 0.629     | 0.805 ± 0.046     | 0.811 ± 0.060 | 0.643     |
| S Hemisphere | 127.7 ± 7.7       | 129.2 ± 9.4    | 0.38      | 0.401 ± 0.024     | 0.406 ± 0.030 | 0.367     |
| I Hemisphere | 128.5 ± 7.9       | 128.9 ± 10.2   | 0.828     | 0.403 ± 0.026     | 0.405 ± 0.032 | 0.721     |
| Temporal     | 119.5 ± 8.3       | 120.2 ± 9.3    | 0.595     | 0.188 ± 0.013     | 0.189 ± 0.015 | 0.609     |
| Superior     | 131.0 ± 8.1       | 131.9 ± 9.8    | 0.626     | 0.206 ± 0.013     | 0.207 ± 0.015 | 0.599     |
| Nasal        | 130.4 ± 8.8       | 133.5 ± 11.4   | 0.191     | 0.205 ± 0.014     | 0.210 ± 0.018 | 0.193     |
| Inferior     | 131.4 ± 8.4       | 130.6 ± 11.0   | 0.946     | 0.206 ± 0.013     | 0.205 ± 0.017 | 0.981     |
| Perifovea    | 112.7 ± 5.3       | 113.9 ± 8.1    | 0.2       | 1.415 ± 0.067     | 1.430 ± 0.103 | 0.193     |
| S Hemisphere | 112.8 ± 5.6       | 114.3 ± 8.4    | 0.195     | 0.709 ± 0.035     | 0.718 ± 0.053 | 0.182     |
| I Hemisphere | 112.4 ± 5.5       | 113.3 ± 8.3    | 0.279     | 0.707 ± 0.035     | 0.712 ± 0.052 | 0.309     |
| Temporal     | 106.3 ± 6.3       | 107.4 ± 7.5    | 0.268     | 0.334 ± 0.020     | 0.337 ± 0.024 | 0.313     |
| Superior     | 112.0 ± 5.8       | 112.8 ± 8.6    | 0.379     | 0.352 ± 0.018     | 0.354 ± 0.027 | 0.404     |
| Nasal        | 121.7 ± 8.1       | 124.8 ± 9.9    | 0.133     | 0.383 ± 0.026     | 0.392 ± 0.031 | 0.127     |
| Inferior     | 110.0 ± 5.4       | 110.4 ± 8.6    | 0.49      | 0.346 ± 0.017     | 0.346 ± 0.027 | 0.521     |

Notes: The unit of measurement thicknesses and volumes were μm and mm³, respectively. Values represented as mean ± SD and analysis made by Mann-Whitney U test.

Abbreviations: S superior, I inferior
Some symptoms of pachychoroid spectrum disorder, including dilated choroidal vessels (i.e. pachyvessels and retinal pigment epitheliopathy), were observed in patient group. Dilated choroidal vessels were observed in 48 (71.6%) eyes and retinal pigment epitheliopathy was evident in 4 (6.0%) eyes (Fig. 1). The mean SFCT (380.3 ± 12.40 μm) was significantly thicker, compared to the control group [28] (310.7 ± 57.5 μm) (P < 0.001) (Fig. 4).

### Table 3 Comparison of the Outer Retinal Thickness between the COVID-19 Patients (N=25) and Control Group (N=60)

| Variable | Retinal Thickness | Retinal Volume |
|----------|------------------|---------------|
|          | Control | Case | P-value | Control | Case | P-value |
| Fovea    | 177.9 ± 11.3     | 179.3 ± 11.3 | 0.71 | 0.140 ± 0.009 | 0.141 ± 0.009 | 0.717 |
| Parafovea| 180.7 ± 8.7      | 181.9 ± 10.5 | 0.559 | 1.136 ± 0.054 | 1.143 ± 0.066 | 0.589 |
| S Hemisphere | 181.0 ± 9.2 | 182.8 ± 10.9 | 0.566 | 0.569 ± 0.029 | 0.574 ± 0.034 | 0.524 |
| I Hemisphere | 180.5 ± 8.9 | 181.0 ± 10.6 | 0.728 | 0.567 ± 0.028 | 0.568 ± 0.033 | 0.78 |
| Temporal | 1799 ± 10.0      | 1836 ± 13.1 | 0.313 | 0.283 ± 0.016 | 0.288 ± 0.021 | 0.339 |
| Superior | 181.5 ± 9.2      | 183.0 ± 11.0 | 0.54 | 0.285 ± 0.014 | 0.288 ± 0.017 | 0.537 |
| Nasal    | 181.2 ± 10.9     | 180.6 ± 10.2 | 0.761 | 0.285 ± 0.017 | 0.284 ± 0.016 | 0.75 |
| Inferior | 180.3 ± 8.9      | 180.4 ± 11.2 | 0.981 | 0.283 ± 0.014 | 0.283 ± 0.017 | 0.996 |
| Perifovea| 170.1 ± 6.7      | 171.6 ± 8.9 | 0.175 | 2.137 ± 0.085 | 2.156 ± 0.111 | 0.168 |
| S Hemisphere | 171.8 ± 7.3   | 173.6 ± 8.8 | 0.143 | 1.079 ± 0.046 | 1.091 ± 0.056 | 0.14 |
| I Hemisphere | 168.4 ± 7.0 | 169.4 ± 9.3 | 0.377 | 1.057 ± 0.044 | 1.065 ± 0.058 | 0.328 |
| Temporal | 165.5 ± 6.9      | 168.8 ± 9.4 | 0.078 | 0.518 ± 0.023 | 0.530 ± 0.030 | 0.054 |
| Superior | 172.3 ± 7.7      | 174.9 ± 9.7 | 0.08 | 0.541 ± 0.024 | 0.550 ± 0.031 | 0.073 |
| Nasal    | 176.1 ± 10.5     | 174.9 ± 9.4 | 0.881 | 0.553 ± 0.033 | 0.549 ± 0.030 | 0.90 |
| Inferior | 166.3 ± 7.2      | 167.6 ± 9.9 | 0.372 | 0.522 ± 0.023 | 0.527 ± 0.031 | 0.367 |

Notes: The unit of measurement thicknesses and volumes were μm and mm³, respectively. Values represented as mean ± SD and analysis made by Mann-Whitney U test.

Abbreviations: S superior, I inferior

### Macular choroidal analysis

Some symptoms of pachychoroid spectrum disorder, including dilated choroidal vessels (i.e. pachyvessels and retinal pigment epitheliopathy), were observed in patient group. Dilated choroidal vessels were observed in 48 (71.6%) eyes and retinal pigment epitheliopathy was evident in 4 (6.0%) eyes (Fig. 1). The mean SFCT (380.3 ± 12.40 μm) was significantly thicker, compared to the control group [28] (310.7 ± 57.5 μm) (P < 0.001) (Fig. 4).

### Discussion

In this study, the macular SD-OCT findings in retinal and choroidal layers of patients recovered from COVID-19 were evaluated, and subfoveal choroidal, as well as inner-, outer-, and full- retinal thickness and volume of choroidal thickness in COVID-19 patients and healthy controls.
the recovered COVID-19 patients were compared with those in healthy control subjects. Hyperreflective lesions in all retinal layers and unremarkable incremental patterns in macular retinal thickness and volume were noted in patients with a history of COVID-19. Some features of pachychoroid spectrum disorder, including pachyvessels, retinal pigment epitheliopathy, and significantly thicker SFCT was also observed in these patients.

Marinho et al. were the first investigators to report abnormal retinal OCT findings in patients (n = 12) with COVID-19 [11]. They noticed hyperreflective lesions at the level of GCL and IPL, and also reported fine Cotton-Wool Spots (CWS) and microhemorrhages along with the retinal arcades in four patients, suggesting an inflammatory or ischemic process. In a later editorial article, Vavvas et al. raised some concerns regarding the interpretation of the OCT and fundus findings in COVID-19 patients [12]. They suggested that as CWS were very subtle and could be due to some comorbid conditions, the results provided by Marinho et al. should be interpreted with caution. Since then numerous and interesting studies have been published on the subject of OCT and OCTA findings in the COVID-19 patients [13–27]; however, the results obtained in these studies have been very different and sometimes contradictory. The more time passes from the onset of this epidemic, the more we know about the specific effects of this disease on the neurosensory tissues of the eye. In this study, the detailed SD-OCT quantitative and qualitative analysis of the retinal and choroidal structure and thickness in patients with a recent history of COVID-19 was reported and the obtained data were compared with those from the healthy control group. One of the strengths of the present study is the elimination of all severe cases of the disease. Hospitalization, steroid consumption, the need for oxygen, and multiorgan failure were all confounding and destructive factors that might have affected the results.

SARS-CoV-2 replication will be initiated after binding to epithelial cells in the nasopharynx and the nasal cavity. ACE2 has been found as the main receptor for SARS-CoV-2 [30]. ACE2 is an enzyme in cell membranes of type II alveolar cells of the lung, enterocytes of the small intestine, arterial and venous endothelial cells, and arterial smooth muscle cells in most organs [31]. The ACE2 has been found in humans, rodents, and the porcine retina. Moreover, the ACE has been reported to be present in the choroid and different cell types of the retina, including Müller cells, ganglion cells, BREC, and photoreceptor cells. Therefore, the retina and choroid are well anticipated to be potential targets of SARS-CoV-2 infection [5].

Some hyperreflective lesions were observed in all retinal layers as reported by Marinho et al. [11]. However, as suggested by Vavvas et al. [12], it is believed that these hyperreflective bands are probably the abnormal and prominent retinal vessels, and the prominence of these findings in COVID-19 patients could be due to vascular involvement (i.e., microthrombosis and vasodilation) associated with this infection. This has been confirmed in recent autopsy specimens, demonstrating vascular dilation and intravascular microthrombosis in these patients [32]. Although hyper reflective foci or dots can be retinal vessels section in OCT but these hyper reflective bands have been seen in different retinal layers and all of them can’t be retinal vessels. They have been reported in different retinal diseases, and could be inflammatory activated and swelled cells, activated microglial cells, focal accumulations of pigment or lipofuscin granules or small intraretinal proteins or lipid exudates deposits due to the breakdown of the blood-retinal barrier [33].

Reinhold et al. also reported fibrin microthrombi in choroidal microvasculature, endothelial swelling, and congestion of choroidal vessels in COVID-19 patients. Moreover, some features of the pachychoroid spectrum of disorders were noted in this study, including increased SFCT, presence of pachyvessels, and retinal pigment epitheliopathy. Based on the results of previous studies, murine coronavirus induced a biphasic retinal disease in adult mice. The early phase of this disease was associated with inflammation, including retinal vasculitis and viral replication, and the late phase was associated with retinal degeneration [34–36]. Therefore, it can be hypothesized that choroidal thickening in COVID-19 patients may happen in two phases, including an initial inflammatory phase with increased vascular permeability followed by a late apoptotic phase with infiltration of the retina by inflammatory cells. However, there is no direct evidence for this claim. Increased choroidal thickness in COVID-19 cases can be attributed to choroidal vascular dilation as an autoregulatory response to hypoxia and hypercapnia. The mean SFCT in our patients was almost 70μm higher than that in normal subjects. Despite the limited accuracy of SFCT measurement, Rahman et al. reported that a change in SFCT more than 32μm is more than interobserver variability and could be a real change [37].

The results of previous studies conducted on structural and vascular changes in choroid and macula are very different and inconsistent. Burgos-Blasco et al. [13] investigated the peripapillary and macular layer thicknesses in 90 recovered COVID-19 patients and found decreases in macular RNFL and an increase in GCL thickness in COVID-19 patients. Cetinkaya et al. [14] selected the hospitalized patients with COVID-19 and treated them with favipiravir, moxifloxacin, and heparin without the need for intubation. The SS-OCT measurements showed no retinal neurodegenerative and choroidal thickness...
alterations; therefore, they concluded that insignificant results might be due to the examination of the patients in the early period of the COVID-19 after treatment. Their results differed from those obtained in the present study in terms of choroidal thickness and not retinal thickness. Oren B, et al. [15] evaluated 35 patients in the COVID-19 group 14–30 days after the onset of the COVID-19 symptom. In their study, the mean value of central macular thickness was significantly high despite the thinner ganglion cell layer and inner nuclear layer. They did not find any significant change in RNFL thickness. González-Zamora et al. [16] found thinner ganglion cell layer (GCL) and thicker RNFL, compared to controls in their study. Results of a study conducted by Hepokur M., et al. [24] was inconsistent with those obtained in the present study and other studies in terms of choroidal thickness, and they found that choroidal thickness was reduced in all measured areas and this decrease affected all choroidal layers. Fırat M [25] evaluated the treatment of COVID-19 patients without comorbidities and concluded that choroidal and retinal thicknesses were not affected in patients with recent mild COVID-19. Their study was similar to the present study in the term of patients’ selection; however, it was different in the term of choroidal thickness changes in the patients. Dominika et al. [26] evaluated 156 eyes of post-COVID-19 patients and 98 eyes of subjects. The OCT examination did not detect any significant changes in morphology or morphometry of the optic nerve, retina, or retina vessels due to COVID-19. These multiple studies with different results indicate the importance of a large sample size study that considers multiple confounding factors (e.g., disease severity) into account, in certain stages of the disease.

Despite different results obtained in different studies conducted on retinal and choroidal layers and thickness based on OCT assessment, there is more consensus on reduced vascular density in the macular region, according to OCTA findings. Decreased vascular density in macula was found in multiple studies, and they have concluded that reduced vessel density of retinal capillary plexus detected in COVID-19 may result in retinal vascular complications and microvascular alterations in COVID-19 patients [16–23].

In conclusion, the results of this study showed that patients with COVID-19 developed not statistically significant thickening in retinal layers which can demonstrate choroidal changes similar to that in patients with the pachychoroid spectrum. It was also found that in COVID-19 patients, hyperreflective lesions are present in all retinal layers and the findings of the current study indicate that retina and choroid could be involved in patients with COVID-19. These findings highlight the necessity of comprehensive ophthalmic examinations in these patients.

Acknowledgements
We would like to thank Minoo Armand, Soosan Helmi, Mitra Mahsouli and Masoumeh Mizban for their kind assistance with this research project. Authors also would like to thank Mr. Amir Reza Samad Zadeh, for his support with PPE for examinations. It is a pleasure for us to also acknowledge the kind supports of Capt. Kaveh Aram.

Financial disclosure
None of the authors has a conflicting financial or propriety interest to disclose.

Financial support
This study was supported by an unrestricted institutional grant of Vice-Chancellor of Research of Mashhad University of Medical Sciences for this research project (Grant Number: 990069). The funding organization had no role in the design or conduct of this research project.

Authors’ contributions
All authors contributed to conception and study design. All authors agreed to be accountable for all aspects of the work. All authors made critical revision and final approval on the manuscript. The author(s) read and approved the final manuscript.

Funding
The authors would like to acknowledge the financial support of Vice-Chancellor of Research, Mashhad University of Medical Sciences, Mashhad, Iran for this research project (Grant Number: 990069).
Available data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
All the included subjects were completely notified about the study protocol. The study was approved by the institutional review board at Mashhad University of Medical Sciences (IR.MUMS.REC.1399.104).

Consent for publication
Informed consent for images and data publication and identifying clinical details was obtained from the patients.

Competing interests
The authors declare that they do not have any financial interest to disclose and they have no conflict of interest.

Author details
1 Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 2 Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 3 Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 4 Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Received: 5 November 2021 Accepted: 2 June 2022
Published online: 18 June 2022

References
1. Zhou Z, Kang H, Li S, Zhao X (2020) Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms. J Neurol 267:1–6
2. Liu M-Y, Zheng B, Zhang Y, Li J-P (2020) Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019. Chronic Dis Transl Med 6(2):98–105
3. Choudhary R, Kapoor MS, Singh A, Bodakhe SH (2017) Therapeutic targets of renin-angiotensin system in ocular disorders. J Curr Ophthalmol 29(1):7–16
4. Abrishami M, Tohidinezhad F, Daneshvar R, Omidtabrizi A, Amini M, Sedaghat A et al (2020) Ocular manifestations of hospitalized patients with COVID-19 in northeast of Iran. Ocul Immunol Inflamm 28(3):391–395
5. Seih IJ, Anderson DE, Kang AEZ, Wang L, Rao P, Young BE et al (2020) Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients. Ophthalmology. 127:977–979
6. Mungmungpuntrapim R, Wiwanitkit V (2020) Ocular manifestation, eye protection, and COVID-19. Graefes Arch Clin Exp Ophthalmol 258(6):1339
7. Goyal M, Murthy S, Annum S (2021) Retinal manifestations in patients following COVID-19 infection: a consecutive case series. Indian J Ophthalmol 69(5):1275–1282
8. Nasin N, Sharifi H, Bazrafshan A, Noori A, Karamouzian M, Sharifi A (2021) Ocular manifestations of COVID-19: a systematic review and Meta-analysis. J Ophthalmic Vis Sci Res 18(1):103–112
9. Kumar KK, Sampiritha UC, Prakash AA et al (2021) Ophthalmic manifestations in the COVID-19 clinical spectrum. Indian J Ophthalmol 69(3):691–694
10. Maninho PM, Marcos AAA, Romano AC, Nascimento H, Belfort Jr R (2020) Retinal findings in patients with COVID-19. Lancet. 395(10237):1610
11. Vavas DG, Sarraf D, Sadek SR, Elliott D, Ehlers JP, Waheed NK et al (2020) Concerns about the interpretation of OCT and fundus findings in COVID-19 patients in recent lancet publication. Eye (Lond) 34:1–2
12. Burgos-Blasco B, Guermes-Villalobos N, Vidal-Villalobos B et al (2021) Optic nerve and macular optical coherence tomography in recovered COVID-19 patients. Eur J Ophthalmol 32:628–636
13. Cetinkaya T, Kurt MM, Akpolat C (2021) Assessment of retinal neurodegeneration and choroidal thickness in COVID-19 patients using swept-source OCT technology. Klin Monatsbl Augenheilkd 238:1092–1097
14. Oren B, Aksoy Aydemir G, Aydemir E, Atesoglu H, Goker VS, Kuztoprak H, Ozcelik KC (2021) Quantitative assessment of retinal changes in COVID-19 patients. Clin Exp Optom 104:1–6
15. González-Zamora J, Bilbao-Malavé V, Gándara E, Casablanca-Piñera A, Boquerana-Ventosa C, Landecho MF, Zarzarran-Ventura J, García-Layaana A (2021) Retinal microvascular impairment in COVID-19 bilateral pneumonia assessed by optical coherence tomography angiography. Biomedicines. 9(3):247
16. Sim R, Cheung G, Ting D, Wong E, Wong TY, Yeo I, Wong CW (2021) Retinal microvascular signs in COVID-19. The British journal of ophthalmology, biophthalmol-2020-318236. Advance online publication.
17. Abrishami M, Emamverdian Z, Shoebi N, Omidtabrizi A, Daneshvar R, Saeedi Rezvani T, Saeedian N, Eslami S, Mazloum M, Sadda S, Sarraf D (2021) Optical coherence tomography angiography analysis of the retina in patients recovered from COVID-19: a case-control study. Can J Ophthalmol 56(1):24–30
18. Turk IC, Dogan CU, Guven D, Kutucu OK, Gul C (2021) Optical coherence tomography angiography findings in patients with COVID-19. Can J Ophthalmol 56(2):83–87
19. Cennamo G, Reibaldi M, Montorio D, D'Andrea L, Fallico M, Triassi M (2021) Optical coherence tomography angiography features in post-COVID-19 pneumonia patients: a pilot study. Am J Ophthalmol 227:182–190
20. Zapata MA, Banderas García S, Sánchez-Moltavská A, Falcó A, Otero-Romero S, Arcos G, Velazquez-Villoria D, García-Anumí J (2020) Retinal microvascular abnormalities in patients after COVID-19 depending on disease severity. Br J Ophthalmol 106:559–563
21. Hazar L, Karahan M, Vural A, Evi A, Ederm S, Dursun ME, Keklikçi U (2021) Macular vessel density in patients recovered from COVID 19. Photodign Photodyn Ther 34:102267
22. Bilbao-Malavé V, González-Zamora J, Saenz de Viteri M, de la Puente M, Gándara E, Casablanca-Piñera A, Boquerana-Ventosa C, Zarzarran-Ventura J, Landecho MF, García-Layaana A (2021) Persistent retinal microvascular impairment in COVID-19 bilateral pneumonia at 6-months follow-up assessed by optical coherence tomography angiography. Biomedicines. 9(5):502
23. Hepokur M, Gunes M, Durmus E, Aykut V, Eser F, Duguz H (2021) Long-term follow-up of choroidal changes following COVID-19 infection: analysis of choroidal thickness and choroidal vascularity index. Can J Ophthalmol. 2021 Jul S:50008:1418(21)00246-5.
24. Firat M, Kobat S (2021) How are central foveal and choroidal thickness affected in patients with mild COVID-19 infection? Br J Basic Med Sci 21:782–786
25. Szkody D, Wylegala E, Sujka-Franczak P, Chalista-Twardzik E, Fiołka R, Tomczyk T, Wylegala A (2021) Retinal OCT Findings in Patients after COVID Infection. J Clin Med 10(15):3233
26. Hazar L, Karahan M, Vural A, Evi A, Ederm S, Dursun ME, Keklikçi U (2021) Macular vessel density in patients recovered from COVID 19. Photodign Photodyn Ther 34:102267
27. Tohidinezhad F, Khorsand A, Zakavi SR et al (2020) The burden and predisposing factors of non-communicable diseases in Mashhad University of Medical Sciences personnel: a prospective 15-year organizational cohort study protocol and baseline assessment. BMC Public Health 20(1):1637 Published 2020 Nov 2
28. Gallego-Pinzado R, Dolc-Marco R, Gómez-Ulla F, Mijen S, Freund KB (2014) Pachychoroid diseases of the macula. Med Hypothesis Discov Innov Ophthalmol 3(4):111–115
29. Wan Y, Shang J, Baric RS, Li F (2020) Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 94(7):e00127–e00120
30. Szkodny D, Wylegala E, Sujka-Franczak P, Chalista-Twardzik E, Fiołka R, Tomczyk T, Wylegala A (2021) Retinal OCT Findings in Patients after COVID Infection. J Clin Med 10(15):3233
31. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H (2004) Structural studies of SARS coronavirus. J Virol 94(7):e00127–e00120
32. Published 2020 Nov 2
33. Tohidinezhad F, Khorsand A, Zakavi SR et al (2020) The burden and predisposing factors of non-communicable diseases in Mashhad University of Medical Sciences personnel: a prospective 15-year organizational cohort study protocol and baseline assessment. BMC Public Health 20(1):1637 Published 2020 Nov 2
34. Gallego-Pinzado R, Dolc-Marco R, Gómez-Ulla F, Mijen S, Freund KB (2014) Pachychoroid diseases of the macula. Med Hypothesis Discov Innov Ophthalmol 3(4):111–115
35. Wan Y, Shang J, Baric RS, Li F (2020) Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 94(7):e00127–e00120
36. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H (2004) Structural studies of SARS coronavirus. J Virol 94(7):e00127–e00120
37. Published 2020 Nov 2
32. Reinhold A, Tzankov A, Matter M, Mihic-Probst D, Scholl HPN, Meyer P (2021) Ocular pathology and occasionally detectable intraocular SARS-CoV-2 RNA in five fatal COVID-19 cases. Ophthalmic Res 64(5):785–792
33. Turgut B, Yildirim H (2015) The causes of hyperreflective dots in optical coherence tomography excluding diabetic macular edema and retinal venous occlusion. Open Ophthalmol J 9:36–40
34. Vinores SA, Wang Y, Vinores MA, Derevyanik NL, Shi A, Klein DA et al (2001) Blood-retinal barrier breakdown in experimental coronavirus retinopathy: association with viral antigen, inflammation, and VEGF in sensitive and resistant strains. J Neuroimmunol 119(2):175–182
35. Papermaster DS, Windle J (1995) Death at an early age. Apoptosis in inherited retinal degenerations. Invest Ophthalmol Vis Sci 36(6):977–983
36. Wang Y, Detrick B, Yu ZX, Zhang J, Chesky L, Hooks JJ (2000) The role of apoptosis within the retina of coronavirus-infected mice. Invest Ophthalmol Vis Sci 41(10):3011–3018
37. Rahman W, Chen FK, Yeoh J, Patel P, Tufail A, Da Cruz L (2011) Repeatability of manual subfoveal choroidal thickness measurements in healthy subjects using the technique of enhanced depth imaging optical coherence tomography. Invest Ophthalmol Vis Sci 52(5):2267–2271
38. Abrishami M, Hassanpour K, Hosseini S, Emamverdian Z, Ansari-Astaneh MR, Zamani G, Gharib B, Abrishami M (2022) Macular vessel density reduction in patients recovered from COVID-19: a longitudinal optical coherence tomography angiography study. Graefes Arch Clin Exp Ophthalmol 260(3):771–779
39. Abrishami M, Hassanpour K, Zamani G, Hosseini SM, Shoeibi N, Emamverdian Z, Zamani A, Amini N, Abrishami M (2022) Longitudinal alterations of retinal and choroidal structure in patients recovered from COVID-19. J Ophthalmol 2022:4123328

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.